BioHarvest Sciences Inc. Q2 2025 Earnings Call Recap: Key Takeaways
ByAinvest
Monday, Aug 11, 2025 1:26 pm ET1min read
BHST--
The quarter's highlights included a 28% growth in core VINIA® capsule business and a 100% increase in new product sales. Additionally, BioHarvest secured a new Stage 1 CDMO contract to develop a plant-based fragrance compound, and successfully completed Stage 1 development for a CDMO project with a Nasdaq-listed pharmaceutical company [1].
The company's gross profit margin expanded by 800 basis points to 60%, primarily due to increased manufacturing scale and improved yields. Total operating expenses increased to $6.9 million, driven by higher marketing spend and CDMO services division costs. Despite the increase in expenses, the company reported a net loss of $4.0 million, with an adjusted EBITDA loss of $1.3 million [1].
Looking ahead, BioHarvest expects third-quarter 2025 revenues of at least $9.1 million and aims to reach adjusted EBITDA breakeven in the fourth quarter. The company plans to launch three growth initiatives in the second half of 2025: the 'Health Pros' Professional Affiliate Program, VINIA® BloodFlow Hydration Solution, and an AI-Enabled CDMO Discovery Phase [1].
References:
[1] https://finance.yahoo.com/news/bioharvest-sciences-reports-second-quarter-113000384.html
BioHarvest Sciences Inc. reported Q2 2025 earnings, with CEO Ilan Sobel highlighting a pivotal quarter for the company. CFO Bar Dichter and Sobel discussed financial performance, industry prospects, and growth strategies. The company emphasized the importance of adjusted EBITDA, a non-IFRS financial measure, and provided a reconciliation in the earnings release on their website.
BioHarvest Sciences Inc. (NASDAQ: BHST) reported robust financial performance for the second quarter of 2025, with CEO Ilan Sobel and CFO Bar Dichter highlighting significant milestones and growth strategies. The company's revenue grew by 41% year-over-year to $8.5 million, driven by strong core capsule sales and new product introductions [1].The quarter's highlights included a 28% growth in core VINIA® capsule business and a 100% increase in new product sales. Additionally, BioHarvest secured a new Stage 1 CDMO contract to develop a plant-based fragrance compound, and successfully completed Stage 1 development for a CDMO project with a Nasdaq-listed pharmaceutical company [1].
The company's gross profit margin expanded by 800 basis points to 60%, primarily due to increased manufacturing scale and improved yields. Total operating expenses increased to $6.9 million, driven by higher marketing spend and CDMO services division costs. Despite the increase in expenses, the company reported a net loss of $4.0 million, with an adjusted EBITDA loss of $1.3 million [1].
Looking ahead, BioHarvest expects third-quarter 2025 revenues of at least $9.1 million and aims to reach adjusted EBITDA breakeven in the fourth quarter. The company plans to launch three growth initiatives in the second half of 2025: the 'Health Pros' Professional Affiliate Program, VINIA® BloodFlow Hydration Solution, and an AI-Enabled CDMO Discovery Phase [1].
References:
[1] https://finance.yahoo.com/news/bioharvest-sciences-reports-second-quarter-113000384.html
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet